Poisoned in the Womb: When Medicine's Mistakes Echo Through Generations - Jill Escher (#19)
Jill Escher came to autism advocacy through the most personal of routes — two profoundly autistic sons and a decades-old medical record that explained everything. In this conversation with Stella, Mia and Bret, she traces how synthetic steroid hormones administered during pregnancy can alter neurodevelopment across generations, and asks the question that medicine has been reluctant to confront: could the same biological disruption be driving today's steep rise in both autism and gender dysphoria?
Jill Escher is not a scientist by training, but she has spent years doing the kind of digging that credentialed researchers should have done long ago. As president of the National Council on Severe Autism and mother to two profoundly autistic sons, she had every reason to search for answers. What she found — buried in a 1965 medical record — sent her down a path that connects the pharmaceutical experiments of the mid-twentieth century to some of the most contested questions in medicine today. The record showed that her mother had received weekly injections of synthetic steroid hormones during pregnancy. That single discovery reframed not just her sons' diagnoses but her understanding of how drugs given to pregnant women can alter gene expression in ways that echo through the next generation — and the one after that. Escher makes clear that this is not fringe thinking: the damage done by diethylstilbestrol, better known as DES, is well documented, even if its lessons have gone largely unlearned. DES was prescribed to millions of women over several decades to prevent miscarriage. It did not work, and it caused measurable harm to children exposed in the womb. Escher argues that the neurological effects have been especially slow to receive serious attention. She extends the concern beyond DES to other synthetic hormones, including anti-miscarriage drugs that remained on the market until 2023, raising the possibility that the damage is not a historical footnote but an ongoing story. One of the most striking parts of this conversation is the thread Escher draws between prenatal hormone exposure and the concurrent rises in autism and gender dysphoria. The hosts press her carefully on this — the connection is not established as settled science — but the hypothesis is coherent and, crucially, testable. If certain developing brains are made more vulnerable by in-utero chemical exposure, the implications for how we understand gender dysphoria in young people are profound. It would mean that the rush to social and medical transition may be treating a symptom without asking what caused the underlying neurodevelopmental difference. What comes through clearly in the discussion is the frustration Escher shares with Stella, Mia and Bret about institutional silence. Regulatory agencies knew enough about DES to act; researchers have enough data to ask hard questions about successor drugs. But the incentives within medicine — commercial, reputational, legal — create pressure to look away. The hosts bring their characteristic willingness to sit with uncomfortable evidence, and Escher, as a parent rather than a professional insider, is free to name what she sees without the hedging that often softens these conversations. This is an episode for anyone who has wondered why rates of autism and gender dysphoria have climbed so steeply and so recently, and who suspects the answers will not come from the institutions most responsible for providing them. Escher's call is modest and hard to argue with: look at the data, fund the research, and take seriously the possibility that medicine's past mistakes are still shaping the present.
Watch and subscribe on YouTube
Open this episode on the Beyond Gender channel
